Articles Written by:    MATTHEW PERRONE     

« Previous  |  Next »

Abbott CEO's pay falls on reduced stock options

The chairman and CEO at Abbott Laboratories received a 13 percent drop in total compensation last year, mainly as a result of reduced stock options. The North Chicago-based company disclosed in a regulatory filing Monday that Miles White's total ...

From MATTHEW PERRONE, TheNewsTribune.com,  15 Mar 2010
Related Topics: Abbott Laboratories,  Securities and Exchange Commission,  Advanced Medical Optics, Inc.

Boston Scientific suspends defibrillator sales

WASHINGTON - Medical device maker Boston Scientific said Monday it is suspending sales of its heart-shocking defibrillator implants after uncovering a documentation error with the manufacture of the top-selling devices. ...

From MATTHEW PERRONE, Atlanta Journal Constitution Vendor,  15 Mar 2010
Related Topics: Boston Scientific,  Food and Drug Administration,  Medtronic, Inc.,  St. Jude Medical, Inc.

Boston Scientific suspends sales of top-selling heart defibrillator devices

WASHINGTON — Medical device maker Boston Scientific said Monday it is suspending sales of its heart-shocking defibrillator implants after uncovering a documentation error with the manufacture of the top-selling devices. The Natick, Mass.-based company ...

From MATTHEW PERRONE, Simple Thoughts,  15 Mar 2010
Related Topics: Boston Scientific,  Food and Drug Administration,  NYSE,  Medtronic, Inc.,  NASDAQ

FDA warns about Plavix effectiveness

WASHINGTON — The US Food and Drug Administration is adding its strongest warning to the label for Plavix, cautioning that some patients do not respond to the blood thinner. The FDA said in a statement yesterday that certain patients with a genetic ...

From MATTHEW PERRONE, Boston Globe,  12 Mar 2010
Related Topics: Food and Drug Administration,  Eli Lilly & Co,  Sanofi-Aventis,  Bristol-Myers Squibb

US warning: some patients cannot process Plavix

The U.S. Food and Drug Administration is adding its strongest warning to the label for Plavix, cautioning that some patients do not respond to the blockbuster blood thinner. The FDA said in a statement Friday that certain patients with a genetic ...

From MATTHEW PERRONE, Taiwan News,  12 Mar 2010
Related Topics: Food and Drug Administration,  Eli Lilly & Co,  Bristol-Myers Squibb,  Sanofi-Aventis,  Pfizer Inc.

FDA warning: some patients cannot process Plavix

WASHINGTON - The Food and Drug Administration is adding its strongest warning to the label for Plavix after reports that some patients cannot process the blockbuster blood thinner. ...

From MATTHEW PERRONE, Atlanta Journal Constitution Vendor,  12 Mar 2010
Related Topics: Food and Drug Administration,  Bristol-Myers Squibb,  Sanofi-Aventis,  Pfizer Inc.

FDA: Medtronic brain stimulator missed study goal

MATTHEW PERRONE, AP Business Writer | WASHINGTON The Food and Drug Administration said Wednesday a nerve stimulating implant from Medtronic failed to significantly reduce seizures in epilepsy patients. Medtronic Inc., the world's largest medical device ...

From MATTHEW PERRONE, San Diego Union-Tribune,  10 Mar 2010
Related Topics: Medtronic, Inc.,  Food and Drug Administration,  Cyberonics, Inc.

FDA approves Botox for elbow, wrist, finger spasms

WASHINGTON — The Food and Drug Administration said Tuesday it approved Allergan's botulinum-based drug Botox to treat spasms of the elbow, wrist and fingers. Botox is most famous for it's ability to smooth frown lines on aging foreheads, but the drug ...

From MATTHEW PERRONE, Middletown Journal,  9 Mar 2010
Related Topics: Allergan, Inc.,  Food and Drug Administration,  Pfizer Inc.

FDA panel favors approval for InterMune drug

WASHINGTON — Federal health advisers on Tuesday voted in favor of an experimental drug from InterMune Inc., despite mixed evidence of whether it provides significant benefits for patients with a rare lung disease. The Food and Drug Administration's ...

From MATTHEW PERRONE, Middletown Journal,  9 Mar 2010
Related Topics: InterMune, Inc.,  Food and Drug Administration

Intermune shares surge as FDA reviews lung drug

WASHINGTON - Shares of drug developer InterMune Inc. surged Friday after federal health officials posted their review of the experimental drug pirfenidone, which is designed to treat a rare lung disease. ...

From MATTHEW PERRONE, Atlanta Journal Constitution Vendor,  5 Mar 2010
Related Topics: InterMune, Inc.,  Food and Drug Administration

« Previous  |  Next »

Who is This?

Help us add to our database, by linking this writer their entry in Wikipedia or Source Watch, or by suggesting that we remove it from our index.

Suggest an Entry

Enter a url from sourcewatch.org or wikipedia.org:


recommend removal

close